4月19日，杭州安道藥業(yè)有限公司和Kind制藥有限責任公司（“安道藥業(yè)”），和其首席執(zhí)行官劉棟博士和首席科學官鄧紹江博士宣布他們解決了與FibroGen,Inc. (琺博進)關于安道藥業(yè)的缺氧誘導因子脯氨酸羥基化酶抑制劑（HIF-PHI）最近的技術爭端。各方已經同意撤回彼此之間關于這項HIF-PHI技術的所有待解決的法律訴訟，而無需任何一方支付費用。
HIF-PHIs是一類可用于治療貧血的化合物。安道藥業(yè)的HIF-PHI藥物候選化合物AND017目前正在進行臨床試驗，用于治療慢性腎?。–KD）患者的貧血。由于達成和解，安道藥業(yè)可以繼續(xù)開發(fā)AND017和其它在其研發(fā)管線中的HIF-PHIs。安道藥業(yè)公司首席執(zhí)行官劉博士表示：“我們很高興這些爭端已經得到全面和最終的解決。解決了這些爭端之后，我們可以專注于推進創(chuàng)新管線產品的上市。”
Kind Pharmaceuticals Announces Settlement
Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC (“Kind Pharmaceuticals”), together with its Chief Executive Officer Dr. Dong Liu and Chief Scientific Officer Dr. Shaojiang Deng, announced a resolution of their recent dispute with FibroGen, Inc. regarding Kind Pharmaceuticals’ hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF- PHI) technology. The parties have agreed to withdraw all pending legal proceedings between them regarding this HIF-PHI technology, without payment by either party.
HIF-PHIs are a class of compounds that can be used to treat anemia. Kind Pharmaceuticals’ HIF-PHI drug candidate, AND017, is currently being studied in a clinical trial for the treatment of anemia in chronic kidney disease (CKD) patients. As a result of the settlement, Kind Pharmaceuticals remains free to develop AND017 and other HIF-PHIs in its pipeline. Dr. Liu, Chief Executive Officer of Kind, commented: “Kind is pleased that these disputes have been fully and finally resolved. With these disputes behind us, Kind can now focus on advancing its innovative pipeline of products to the market.”
合作咨詢
肖女士
021-33392297
Kelly.Xiao@imsinoexpo.com
2006-2025 上海博華國際展覽有限公司版權所有（保留一切權利）
滬ICP備05034851號-57
